VectivBio reunites ex-Therachon management, VCs for short bowel program

VectivBio launches with $35M, hopes to build pipeline beyond the asset it was created to house

Eight months after a venture syndicate gained an exit via the sale of dwarfism company Therachon to Pfizer, the same investors have reunited to supply a $35 million round for VectivBio, a new spinout created to house a short bowel syndrome program left behind in the acquisition.

VectivBio AG will reunite several members of Therachon’s management team, as well as a syndicate

Read the full 616 word article

User Sign In